Bicara Therapeutics BCAX Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's weighted average exercise price of outstanding options?
- Bicara Therapeutics (BCAX) reported weighted average exercise price of outstanding options of $10.74 in Q1 2026.
- How has Bicara Therapeutics's weighted average exercise price of outstanding options changed year-over-year?
- Bicara Therapeutics's weighted average exercise price of outstanding options increased by 48.1% year-over-year, from $7.25 to $10.74.
- What is the long-term trend for Bicara Therapeutics's weighted average exercise price of outstanding options?
- Over 2 years (2023 to 2025), Bicara Therapeutics's weighted average exercise price of outstanding options has grown at a 41.2% compound annual growth rate (CAGR), from $4.53 to $9.03.
- What does weighted average exercise price of outstanding options mean?
- This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.